<DOC>
	<DOC>NCT01332149</DOC>
	<brief_summary>Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy. This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.</brief_summary>
	<brief_title>Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Male and female subjects aged 18 years or older Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to diabetes mellitus (Type 1 or 2), and symptoms of painful diabetic neuropathy for 6 months to 5 years (inclusive). At the baseline and randomization visits, a score of ≥50 mm on the Visual Analogue Scale, at randomization, subjects must have completed at least 5 daily pain interference diaries, and have an average daily pain score of ≥5 over the past 7 days. Patient who are willing and capable to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Women of childbearing potential are willing to use contraception during study. Subjects with more than 30% decrease on the Pain Visual Analog Scale at randomization as compared to screening; and during the 1 week screening period, with more than one pain score &lt;3 in pain scores. Subject has other kinds of neurological disorder, pain of other reason, or skin condition that could confuse the assessment. Subject with any other serious or unstable condition which in the opinion of the investigator might compromise participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Diabetic Neuropathies</keyword>
	<keyword>Pain</keyword>
	<keyword>Efficacy of pregabalin</keyword>
	<keyword>Placebo controlled</keyword>
</DOC>